Product Information
IMATINIB MESYLATE 400 MG TAB is a generic product labeled by Dr. Reddy's Laboratories Inc., priced at $2.6771 per EA under NDC 43598034531. Its NADAC has been published 312 times since Oct 14, 2020.
FDA first approved this application on Aug 13, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
400 mg/1
Manufacturer
Dr. Reddy's Laboratories Inc.NDC
43598034531
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
IMATINIB MESYLATEApproval Type
Generic (ANDA)
FDA Application
ANDA206547FDA Approved
8/13/2018
TE Code
AB
On Market Since
8/13/2018
Pharmacological Classes
Price Statistics
The NADAC for IMATINIB MESYLATE 400 MG TAB has been published 312 times since Oct 14, 2020, and over the history we have for it it has declined 70.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.6771 per EA |
|---|---|
| All-time high | $8.9088 (Oct 14, 2020) |
| All-time low | $1.4080 (Aug 23, 2023) |
| 52-week high | $3.2150 |
| 52-week low | $2.6771 |
| Median price | $2.7144 |
| Average price | $2.9562 |
| Largest weekly change | -36.2% (Jul 21, 2021) |
| Weeks tracked | 312 |
| Tracking since | Oct 14, 2020 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Dr. Reddy's Laboratories Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Imatinib market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Kinase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of IMATINIB MESYLATE 400 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for IMATINIB MESYLATE 400 MG TAB, manufactured by Dr. Reddy's Laboratories Inc., is $2.6771 per EA (NDC 43598034531), effective Sep 30, 2026.
How has the price of IMATINIB MESYLATE 400 MG TAB changed over time?
Over the history we have for it, the NADAC for IMATINIB MESYLATE 400 MG TAB has declined 70.0%. It has been tracked across 312 weekly CMS publications since Oct 14, 2020.
What are the highest and lowest recorded NADAC prices for IMATINIB MESYLATE 400 MG TAB?
Since Oct 14, 2020, the NADAC for IMATINIB MESYLATE 400 MG TAB has ranged from a low of $1.4080 (Aug 23, 2023) to a high of $8.9088 (Oct 14, 2020), with a median of $2.7144 per EA.
Are there cheaper alternatives to IMATINIB MESYLATE 400 MG TAB?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as IMATINIB MESYLATE 400 MG TAB in a comparable dosage form, but none are currently priced below it.
Who manufactures IMATINIB MESYLATE 400 MG TAB?
IMATINIB MESYLATE 400 MG TAB (NDC 43598034531) is labeled by Dr. Reddy's Laboratories Inc., and CMS classifies it as a generic product.